5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

Yasuteru Sakurai, Mya Myat Ngwe Tun, Yohei Kurosaki, Takaya Sakura, Daniel Ken Inaoka, Kiyotaka Fujine, Kiyoshi Kita, Kouichi Morita, Jiro Yasuda

Research output: Contribution to journalArticlepeer-review


© 2021 Elsevier Inc. The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19, in cell culture. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is worth to be further investigated as an antiviral drug candidate for COVID-19.
Original languageEnglish
JournalBiochemical and Biophysical Research Communications
StatePublished - 19 Mar 2021

Fingerprint Dive into the research topics of '5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro'. Together they form a unique fingerprint.

Cite this